• Skip to main content
  • Skip to footer

Life Sciences British Columbia

  • Members Area |
  • Contact Us
  • SearchSearch
  • About
    • Board of Directors
    • Management
    • Vision & Mission
    • LSBC Hall of Fame
  • Awards
  • Membership
    • Sponsors
    • Members Directory
    • Members Area
    • Membership Benefits
    • Membership Discounts
    • Members Services
    • Members Map
    • Become a Member
  • Events
    • Calendar
    • Webinars
    • Past Events
      • 2023 Events
      • 2022 Events
      • 2021 Events
      • 2020 Events
      • 2019 Events
      • 2018 Events
  • News
    • All News
    • Member News
    • Industry News
    • LSBC in The News
    • Publications
    • BC Labour Market Study
  • Resources
    • All Resources
    • Grants and Funding
      • Funding Competitions
      • Wage Subsidies
    • Academic Institutions
    • Government
      • Federal
      • Provincial and Municipal
    • Association Partners
    • Programs
    • Volunteering
  • Jobs
    • Job Board
    • Post a Job
    • Career Events
  • Contact Us
  • Login

Xenon Pharmaceuticals Inc.

Member Profile

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology-focused therapies to address areas of high unmet medical need, with a focus on epilepsy.

Sector
Biotechnology, Therapeutics
Area of Expertise
  • Drug Delivery
  • Drug Discovery
  • Neurological Diseases
  • Pediatrics
  • Therapeutics
This member is looking for Academic Partnerships , Business Development
Company Stage Clinical Stage, Public Company
Stock Ticker XENE - NASDAQ

We are working On:

Our “Xenon CARES” values are woven into all that we do, and we are united by a common mission to deliver innovative medicines to improve the health of patients with neurological diseases such as epilepsy. The products within our novel proprietary pipeline – including XEN496, XEN1101 and XEN007 – are aimed at treating neurological disorders, with a particular focus on epilepsy. We intend to pursue a variety of development strategies, such as those focused on using a “precision medicine” approach to address rare pediatric disorders, including KCNQ2 epilepsy, as well as those targeting broader patient populations, such as adult patients with focal epilepsy. We also have promising partnered products within our pipeline, such as NBI-921352 with Neurocrine Biosciences and FX301 with Flexion Therapeutics.

We are looking For:

We are a collaborative, ambitious, and driven team with a common mission to deliver innovative medicines to improve the health of patients. And, as a premier neuroscience company, we are committed to enhancing the lives of our employees too. This is an exciting time at Xenon. As our pipeline products advance into later stages of clinical development, we are growing across the organization. We are proud of the talent we have assembled, and we continue to look for smart and determined individuals who thrive in a fast-paced and dynamic work environment to join our team during this transformative time. Check out our current opportunities at: https://can59.dayforcehcm.com/CandidatePortal/en-us/xenon

Member Profile

Biotechnology, Therapeutics

Xenon Pharmaceuticals Inc.

Bronze Sponsor

  • Website www.xenon-pharma.com
  • Phone +1 (604) 484 3300
  • Email info@xenon-pharma.com
  • Address
    200 - 3650 Gilmore Way
    Burnaby, BC
    V5G 4W8
  • Leadership Contact
    Ian Mortimer, President & CEO
    Follow us:
  • Twitter
  • LinkedIn
  • News
  • Jobs

No current content.

March 29, 2023

Senior Vice President, Clinical Development
  • Twitter
  • Linkedin
Tweets by Xenon Pharmaceuticals Inc.
Connect with us LinkedIn

© 2023 Life Sciences BC  |  Privacy Policy

  • Current Jobs
  • Event Calendar
  • All News
  • Member Directory
    Connect with us
  • LinkedIn
  • Twitter
  • Facebook
  • Instagram
Contact Us